Arcieri E S, Pierre Filho P T P, Wakamatsu T H, Costa V P
Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, São Paulo, Brazil.
Eye (Lond). 2008 Feb;22(2):179-83. doi: 10.1038/sj.eye.6702542. Epub 2006 Aug 25.
To evaluate the effects of topical latanoprost, travoprost, and bimatoprost on the blood-aqueous barrier and central corneal thickness (CCT) of patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).
Prospective, randomized, masked-observer, crossover clinical trial.
A total of 34 phakic patients with POAG or OHT with no previous history of intraocular surgery or uveitis completed the study. Patients were randomized to use latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.03% once daily (2000 hours) for 1 month, followed by a washout period of 4 weeks between each drug. Aqueous flare was measured with a laser flare metre. CCT was calculated as the average of five measurements using ultrasound pachymetry. All measurements were performed by a masked observer (1000 h).
There were no statistically significant differences between baseline mean IOP, mean CCT, and mean flare values among the groups. There was no statistically significant increase in mean flare values from baseline in all groups (P>0.05). There were no statistically significant differences between mean flare values among the groups (P>0.05). All medications significantly reduced the mean IOP from baseline (P<0.0001). IOP reduction obtained with travoprost (7.3+/-3.8 mmHg) was significantly higher than that obtained with latanoprost (4.7+/-4.2 mmHg) (P=0.01). A statistically significant reduction in mean CCT (0.6+/-1.3%) from baseline was observed when patients instilled bimatoprost (P=0.01).
Latanoprost, travoprost, and bimatoprost had no statistically significant effect on the blood-aqueous barrier of phakic patients with POAG or OHT. Bimatoprost may be associated with a clinically irrelevant reduction in mean CCT.
评估局部使用拉坦前列素、曲伏前列素和比马前列素对原发性开角型青光眼(POAG)和高眼压症(OHT)患者血-房水屏障及中央角膜厚度(CCT)的影响。
前瞻性、随机、盲法观察、交叉临床试验。
共有34例无眼内手术或葡萄膜炎病史的有晶状体POAG或OHT患者完成了本研究。患者被随机分为每日一次(20:00)使用0.005%拉坦前列素、0.004%曲伏前列素或0.03%比马前列素,为期1个月,每种药物之间有4周的洗脱期。使用激光散射仪测量房水闪光。使用超声测厚仪进行五次测量,计算CCT的平均值。所有测量均由盲法观察者(10:00)进行。
各组间基线平均眼压、平均CCT和平均闪光值无统计学显著差异。所有组的平均闪光值与基线相比均无统计学显著增加(P>0.05)。各组间平均闪光值无统计学显著差异(P>0.05)。所有药物均使平均眼压较基线显著降低(P<0.0001)。曲伏前列素降低的眼压(7.3±3.8 mmHg)显著高于拉坦前列素(4.7±4.2 mmHg)(P=0.01)。当患者滴用比马前列素时,观察到平均CCT较基线有统计学显著降低(0.6±1.3%)(P=0.01)。
拉坦前列素、曲伏前列素和比马前列素对有晶状体POAG或OHT患者的血-房水屏障无统计学显著影响。比马前列素可能与平均CCT的临床无关性降低有关。